Alt_Fuel
Nov 13, 12:46 PM
$VSTM
$RVMD
$TNGX
$ERAS
Positioning relative to the highlighted shift
Verastem’s strategy aligns with Doepke’s view
that combinations are the way forward:
strong single-agent activity with a selective G12D inhibitor
(potentially preferred for that large subgroup
over pan-RAS agents due to selectivity/tolerability)
plus deliberate combo trials in 1L and later lines.
Analysts have noted its [ Verastems] data as competitive or superior in the G12D subset compared with pan-RAS agents like daraxonrasib in certain cross-trial views.
Doepke himself has posted positively on the VS-7375 updates (including the 50% 2L ORR and Phase 3 plans) in the context of RVMD and ERAS.
Verastem is one of several companies (alongside Revolution, Tango, Erasca, and others) driving this RAS-focused, combination-heavy wave in PDAC. Cash position was strengthened by a recent
$250M offering, supporting continued development.
https://x.com/i/grok?conversation=2121221416158720203
0 replies